HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HBW US Market News: Awards, Appointments, Actions And Nutrition And Disaster Relief

Executive Summary

Kochanowski retires with CHPA Career Achievement award; Haelon’s Paley chairs CHPA board; House Oversight Committee chair, FTC commissioner speak at NCPA Fly-In; NasoClenz provided to help consumers following East Palestine disaster; CRN’s Mister attends White House End Hunger launch.

You may also be interested in...



People On The Move: Appointments At ANEFP, CHPA, Norgine, InfectoPharm, DSM

A round-up of the latest appointments in Europe's and the US health and wellness industries: Spain's ANEFP elects Martín as president;  US CHPA appoints Parks as senior VP of regulatory and scientific affairs, Norgine hires HRA's Hilton to lead its consumer business; Infectopharm names Weleda's Ammendola as R&D head; and DSM-Firmenich makes management changes.

Consumer Spending On Supplements Helps Trim Chronic Disease Treatment Costs – CRN Study

CRN study on health-care cost savings from use of supplements offers data on reductions in spending on hospitalizations for chronic conditions linked to use of omega-3s, fiber and other supplements as well as on efficacy of certain dietary ingredients in helping prevent chronic conditions.

GSK Consumer Split Set For July, With Emerging Markets And Switch To Drive Growth

GSK will spin-off its consumer health business in July under the name Haleon. The standalone operation expects to outpace market growth rates by expanding in emerging markets, tapping into consumer demand for more natural products and delivering two Rx-to-OTC switches in the US.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel